Table 1.

Distribution of the subjects into groups and the study population

Intervention	Group			Total
	DIM	DIM	Placebo
	100 mg/day	200 mg/day
Number of patients enrolled	26	26	26	78
Date of inclusion of the first patient	10 December 2012	10 December 2012	21 December 2012
Date of inclusion of the last patient	21 November 2013	20 November 2013	20 November 2013
Date of the last visit of the last patient	4 April 2014	5 April 2014	15 April 2014
Eliminated from the study due to withdrawal of consent to participate in the study prior to receiving the first dose of the drug and excluded from the analysis (both safety and efficacy)	1	2	3	6
Eliminated from the study due to withdrawal of consent to participate in the study after the beginning of therapy	2	4	4	10
Ceased to meet the criteria for participation in the study	0	0	0	0
Excluded from the study for safety reasons ahead of schedule	2	1	1	4
Completed visit procedure in 90 days of treatment in accordance with the study protocol and included in the efficacy analysis	22	20	19	61
Stopped taking the drug due to CIN recovery after 90 days of therapy	15	17	10	42
Completed visit procedures after 180 days of treatment in accordance with the study protocol and included in the efficacy analysis	21	19	18	58

CIN cervical intraepithelial neoplasia, DIM 3,3′-diindolylmethane